Get the Stockscreener App
0.7775
4.50%
0.0335
Atossa Therapeutics Inc stock is traded at $0.7775, with a volume of 467.73K.
It is up +4.50% in the last 24 hours and down -9.52% over the past month.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
See More
Previous Close:
$0.744
Open:
$0.76
24h Volume:
467.73K
Relative Volume:
0.42
Market Cap:
$100.43M
Revenue:
-
Net Income/Loss:
$-26.91M
P/E Ratio:
-3.5341
EPS:
-0.22
Net Cash Flow:
$-19.57M
1W Performance:
+0.13%
1M Performance:
-9.52%
6M Performance:
-2.23%
1Y Performance:
-43.25%
1-Day Range:
$0.7448
$0.79
1-Week Range:
$0.7313
$0.7994
52-Week Range:
$0.5526
$1.66
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Name
Atossa Therapeutics Inc
Sector
Industry
Phone
206.588.0256
Address
10202 5TH AVENUE NE, SEATTLE, WA
Compare ATOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
0.7775 | 102.05M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-18 | Initiated | Maxim Group | Buy |
Atossa Therapeutics Inc Stock (ATOS) Latest News
Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer - GuruFocus
13,000 Annual Metastatic Cases: Atossa's New Breast Cancer Drug Trial Could Reshape Treatment - Stock Titan
How to track smart money flows in Atossa Therapeutics Inc.Market Weekly Review & Daily Stock Trend Watchlist - Newser
Measuring Atossa Therapeutics Inc.’s beta against major indicesJuly 2025 Outlook & Long-Term Safe Investment Ideas - Newser
Chart overlay techniques for tracking Atossa Therapeutics Inc.Earnings Performance Report & Weekly Momentum Stock Picks - Newser
Custom watchlist performance reports with Atossa Therapeutics Inc.Analyst Downgrade & Safe Capital Growth Plans - Newser
Technical analysis overview for Atossa Therapeutics Inc. stock2025 Price Action Summary & AI Driven Price Predictions - Newser
Building trade automation scripts for Atossa Therapeutics Inc.Market Trend Report & Reliable Entry Point Alerts - Newser
Using RSI to spot recovery in Atossa Therapeutics Inc.July 2025 Snapshot & Free Real-Time Market Sentiment Alerts - Newser
Institutional scanner results for Atossa Therapeutics Inc.2025 Market WrapUp & Safe Entry Point Identification - Newser
Is It Too Early to Call Recovery in Atossa Therapeutics Inc.Insider Buying & Real-Time Stock Movement Alerts - classian.co.kr
Can momentum traders help lift Atossa Therapeutics Inc.2025 Technical Patterns & Stepwise Entry/Exit Trade Alerts - Newser
Leading vs lagging indicators on Atossa Therapeutics Inc. performanceTrade Exit Report & Comprehensive Market Scan Insights - Newser
Applying sector rotation models to Atossa Therapeutics Inc.Market Risk Analysis & Long-Term Safe Investment Ideas - Newser
Why Atossa Therapeutics Inc. stock attracts strong analyst attention2025 Big Picture & Entry Point Confirmation Signals - Newser
What does recent volatility data suggest for Atossa Therapeutics Inc.2025 Risk Factors & Expert Curated Trade Setups - Newser
Will Atossa Therapeutics Inc. benefit from macro trendsRisk Management & Verified Short-Term Trading Plans - Newser
New Product Launches: Will They Boost Atossa Therapeutics Inc. Stock in 20252025 Analyst Calls & Safe Entry Point Identification - Newser
Atossa Therapeutics reports progress in breast cancer treatments - MSN
How Atossa Therapeutics Inc. stock performs during market volatilityQuarterly Market Review & Weekly Momentum Picks - newsyoung.net
What the charts say about Atossa Therapeutics Inc. todayWeekly Trend Report & Smart Money Movement Alerts - Newser
What recovery options are there for Atossa Therapeutics Inc.July 2025 EndofMonth & Pattern Based Trade Signal System - Newser
HC Wainwright Expects Reduced Earnings for Atossa Genetics - Defense World
Does Atossa Therapeutics Inc. show high probability of reboundQuarterly Profit Summary & Long Hold Capital Preservation Tips - Newser
Multi asset correlation models including Atossa Therapeutics Inc.Market Growth Summary & Fast Gain Swing Trade Alerts - Newser
Trendlines Converge — Decision Point for Atossa Therapeutics Inc.July 2025 Selloffs & Weekly High Return Stock Opportunities - beatles.ru
Published on: 2025-08-15 04:52:23 - Newser
Atossa Therapeutics Advances Breast Cancer Treatments - TipRanks
Technical Heatmap Flags Atossa Therapeutics Inc. for WatchMarket Volume Summary & Fast Gain Swing Alerts - newsyoung.net
What makes Atossa Therapeutics Inc. stock price move sharplyBuy Signal & Low Drawdown Trading Strategies - Newser
Should you wait for a breakout in Atossa Therapeutics Inc.IPO Watch & Low Drawdown Investment Strategies - Newser
Ranking Atossa Therapeutics Inc. among high performing stocks via toolsTrade Analysis Summary & AI Optimized Trade Strategies - Newser
What does recent volatility data suggest for Atossa Therapeutics Inc. [July 2025 News Drivers]Weekly Breakout Opportunity Watchlist - Newser
Atossa Therapeutics Inc. stock momentum explainedDaily Breakout List with Smart Filters - Newser
H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $7 - 富途牛牛
Positive FDA Feedback and Promising Phase 2 Results Justify Buy Rating for Atossa Therapeutics - TipRanks
Atossa Therapeutics Inc Stock (ATOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atossa Therapeutics Inc Stock (ATOS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Remmel H. Lawrence | Director |
Mar 26 '25 |
Buy |
0.70 |
10,000 |
7,000 |
10,257 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):